IPAT Study

Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid and Tau in Older Adults (IPAT).

Study Description

High blood pressure is a risk factor for Alzheimer’s Disease (AD) and related dementias. The “Impact of Intensive Treatment of Systolic Blood Pressure on Brain Perfusion, Amyloid, and Tau in Older Adults” (IPAT Study) is a 2-arm open-label randomized controlled trial to assess the effects of intensive pharmacological reduction of high blood pressure (SBP) on brain amyloid and tau protein depositions in older adults. Excessive brain amyloid and tau protein depositions are the hallmarks of AD which will be measured with the state-of-the-art Positron Emission Tomography (PET) in the IPAT study.

The study is funded by the National Institute on Aging (NIA), a division of the National Institutes of Health (NIH). Investigators from the following institutions are collaborating on this project:

• University of Texas Southwestern Medical Center
• Texas health Presbyterian Hospital Dallas
• University of Texas, Arlington
• Michigan State University